Topic

Michael Wong is an emeritus board member of the Harvard Business School Healthcare Alumni Association (HBSHAA).

Articles

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

Should Biopharma C-Suites Still Engage With China? A Harvard Business School Healthcare Alumni Association Q&A with Professor F. Warren McFarlan

C-Suites and their boards should remember that digital transformation is a key part of the larger focus of a profound business transformation.

As Biopharma Firms Finalize C-Suite Goals for 2024, Are Their Workforces Prepared to Execute? A Q&A With MIT’s Stephanie L. Woerner, PhD

Mike Hollan is an assistant managing editor for 

 and can be reached at mhollan@mjhlifesciences.com.

Schmidt discusses the recent announcement that Medidata and the NCI extended their partnership an additional five years.

Q&A With Joe Schmidt, EVP, Head of Customer Services and Success at Medidata

Stark discusses pharma’s supply chain and the issues it is facing.

Q&A With Derron Stark, Managing Director of Strategy and Transactions at EY

Meg Rivers is the former managing editor of 

As the industry expands on areas of women’s health with large unmet medical needs, one biotech company is targeting local, vaginal inflammation, specifically for women undergoing IVF and to address other fertility- and reproductive tract-associated health conditions. 

Women’s Health Landscape and New Treatment Approaches on the Horizon

Anne Ollivier is the director of global new products at Sandoz.

C. Kuyler Doyle is the head of discovery, strategy, and new product planning at ProQR Therapeutics.

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.

New Product Planning: The Function's Evolution in Pharma

Scott Braunstein is chairman and CEO of Marinus Pharmaceuticals, Inc.

Disruptive strategies are essential to grow the pharma industry. 

From Concept to Commercialization: Pushing the Envelope

Leslie Sandberg Orne is the president and chief executive officer of Trinity Life Sciences.

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Strategies for Success in an Evolving Commercialization Landscape 

Videos

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses workforce trends in pharma and fostering an environment for psychological safety in this Pharmaceutical Executive Podcast video.

Workforce Trends in Pharma & Psychological Safety

Lisa Henderson is the former group editorial director of 

Now with a seat at the table, growing accountability, and evolving competencies, medical affairs can use its far-reaching influence to change pharma for the better.